"目录号: HY-14153A

GPCR/G ProteinNeuronal Signaling-

Tegaserod马来酸盐是5-HT4激动剂。

5-HT Receptor

相关产品

Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-

生物活性

Description

Tegaserod maleate is a partial agonist of the 5-HT4 receptor; stimulates the peristaltic reflex and accelerates gastrointestinal transit.IC50 value:Target: 5-HT4 agonistIn an in vivo model for peripheral nerve regeneration, mice receiving tegaserod at the site of injury showed enhanced recovery compared to control mice receiving vehicle control as evidenced by functional measurements and histology [1]. Treatment with fluoxetine (10 mg · kg(-1) · day(-1), days 36-42), tegaserod (1 mg · kg(-1) · day(-1), day 43), or the combination of both, reduced visceral hypersensitivity and plasma 5-HT levels [2]. Intravenous or intraduodenal tegaserod (0.3-1.0 mg.kg(-1)) had no inhibitory effect on mesenteric and colonic blood flow. Peroral treatment of rats with alosetron or tegaserod for 7 days did not modify mesenteric haemodynamics at baseline and after blockade of nitric oxide synthesis [3].

Clinical Trial

NCT00511771

Novartis

Irritable Bowel Syndrome With Constipation-Chronic Idiopathic Constipation

NCT00277550

Novartis-Mayo Clinic

Constipation and Dyspepsia

Phase 4

NCT00399659

Novartis

Opioid-induced Constipation

November 2006

Phase 3

NCT00414024

Novartis

Opioid-induced Constipation

February 2007

Phase 3

NCT00390975

Novartis

Gastroparesis-Diabetes

January 2007

Phase 4

NCT00149877

Novartis

Chronic Constipation

April 2004

Phase 4

NCT00171457

Novartis

Heartburn-Dyspepsia

April 2005

Phase 3

NCT00171470

Novartis

Dyspepsia

April 2005

Phase 3

NCT00232102

Novartis

Dyspepsia

September 2004

Phase 3

NCT00232037

Novartis

Dyspepsia

September 2004

Phase 3

NCT00141089

Novartis

Chronic Constipation

March 2004

Phase 3

NCT00348634

Novartis-Temple University-University of Michigan

Chronic Constipation

July 2006

Phase 4

NCT00171522

Novartis

Constipation

May 2005

Phase 4

NCT00171483

Novartis

Gastroesophageal Reflux Disease (GERD)

January 2004

Phase 3

NCT00142974

Novartis

Diabetic Gastropathy

May 2004

Phase 2

NCT00142987

Novartis

IBS-C and IBS With Mixed Bowel Habits

April 2004

Phase 4

NCT00232089

Novartis

Dyspepsia

May 2004

Phase 3

NCT00232024

Novartis

Dyspepsia

January 2004

Phase 3

NCT00171431

Novartis Pharmaceuticals-Novartis

Constipation Predominant-Irritable Bowel Syndrome (IBS-C)

November 2004

Phase 3

NCT00171418

Novartis

Gastroesophageal Reflux Disease (GERD)

June 2003

Phase 3

NCT00365820

Novartis

Constipation

July 2006

Phase 2-Phase 3

NCT00139568

Novartis

Constipation

February 2005

Phase 3

NCT00563615

Hospital Authority, Hong Kong-Novartis Pharmaceuticals

Constipation

November 2004

NCT00563758

Hospital Authority, Hong Kong-Novartis

Constipation-Chronic Disease

December 2004

NCT00149851

Novartis

Symptomatic Gastroespohageal Reflux Disease

January 2004

Phase 2

View MoreCollapse

References

[1].Bushman J, et al. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. Neuropharmacology. 2014 Apr;79:456-66.

[2].Yan C, et al. Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats. Braz J Med Biol Res. 2012 Oct;45(10):948-54.

[3].Painsipp E, et al. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol. 2009 Nov;158(5):1210-26.